Researchers at the University of Illinois have made significant strides in developing a new treatment for estrogen receptor-positive (ER+) breast cancer, which is the most prevalent form of breast cancer in the United States. The newly synthesized compound, known as ErSO-TFPy, has shown promising results in preclinical studies with mice and rats.
In experiments, a single dose of ErSO-TFPy was able to completely eliminate small tumors and significantly reduce the size of larger tumors, ranging from 500 to 1500 mm³. Notably, this treatment did not produce any observed side effects, a crucial advantage over traditional therapies that often result in complications such as blood clots, sexual dysfunction, and osteoporosis. The lead researcher, Dr. Paul Hergenrother, expressed optimism about the compound's potential, highlighting the rarity of a treatment that can effectively shrink and eradicate tumors in such a manner.
Currently, ER+ breast cancer treatments typically involve surgical removal of tumors followed by hormone therapy, which aims to inhibit estrogen that fuels tumor growth. While these treatments have improved the five-year survival rate for breast cancer patients to over 90%, they do not prevent recurrence or resistance, prompting the search for more effective alternatives.
The study, published in the journal ACS Science, indicates that the tumor regression caused by ErSO-TFPy results from rapid necrotic cell death and is independent of immune cell involvement. Additionally, the compound's effectiveness was confirmed in models using transplanted human breast cancer tumors, suggesting its potential applicability in human patients in the future. Researchers are hopeful that ErSO-TFPy could provide a more efficient and less problematic option for treating ER+ breast cancer.